Plain-English translation of NCT05706896 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
This study doesn't follow the usual testing phases โ it may be an observational study or a different type of research.
This pilot study is testing whether injections of umbilical cord blood platelet-rich plasma (CB-PRP) โ a treatment derived from donated umbilical cord blood โ can help slow or stop vision loss in people with dry age-related macular degeneration (AMD), a common eye condition affecting older adults. Researchers will inject the medication into one eye while giving a placebo (sham) injection into the other eye to see if the treatment works. The study will test three different injection schedules to find the best approach.
Dry AMD causes progressive vision loss and currently has very limited treatment options. This study is exploring whether this medication, which is rich in healing compounds, might help protect the eye and slow the damage caused by this condition.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
If you join this study, you will receive a series of injections into one eye, while your other eye receives a placebo injection for comparison. Depending on which group you're assigned to, you'll receive injections either monthly (12 times), every two months (6 times), or every three months (4 times) over the course of the study. Your vision and eye health will be monitored carefully throughout the trial to track whether the treatment helps slow your vision loss.
AI-generated summary from trial data ยท Jun 3, 2026 ยท Not medical advice
Italy
Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Enrollment target
~36 participants
Started
December 2022
Primary completion
June 2023
This trial's estimated completion date has passed โ the record may not be fully up to date.
Age range
65 Years and older
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary โ some teams are faster than others.
Central contact
Maria Cristina Savastano
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first โ no email needed to get started.